Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (1R01AI139536-01)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIH5U19MH114821, NIH5U19MH114821)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 31 August 2021
Accepted: 17 September 2021
First Online: 4 February 2022
Competing interests
: VKK has an ownership interest in and is a member of the SAB for Tizona Therapeutics and is a co-founder of and has an ownership interest in Celsius Therapeutics. NY is an advisor for and/or has equity in Cellarity, Celsius Therapeutics, and Rheos Medicines. The remaining authors declare no competing interests.